Annals of Oncology Advance Access originally published online on March 3, 2005
Annals of Oncology 2005 16(4):538-548; doi:10.1093/annonc/mdi129
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Review |
HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy
Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
* Correspondence to: Dr G. Giaccone, Department of Medical Oncology, Vrije Universiteit Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. Tel: +31-20-4444321; Fax: +31-20-444079; Email: g.giaccone{at}vumc.nl
Therapeutic agents that target the epidermal growth factor receptor (HER1/EGFR) signal pathway, such as small-molecule tyrosine kinase inhibitors and monoclonal antibodies are now advanced in clinical development and two are already licensed for use. Complete/ongoing phase II studies with these agents clearly demonstrate that a small, but significant proportion of patients respond to HER1/EGFR inhibition. However, with our current understanding of tumour biology and genetics, we cannot explain why some patients respond well and others less so or not at all. These differences may be a result of many factors, such as patients' genotype and phenotype, pharmacological and pharmacokinetic differences between agents or the inherent molecular heterogeneity of tumours. In this article, we explore current strategies to identify patients who respond differently and ways to maximise the clinical benefit of these therapies. This includes defining optimal dose and dosing schedules, identifying appropriate combination partners and finding predictive and surrogate markers of response. The association between HER1/EGFR gene mutations in non-small cell lung cancer (NSCLC) tumours and response to HER1/EGFR-targeted agents is also discussed. This may help us to preselect responsive patients, tailor the dose according to the individual's tolerability, or monitor these agents to optimise/interrupt therapy at an early stage.
Key words: HER1/EGFR, Iressa, predictive marker, surrogate market, Tarceva, tyrosine kinase inhibitor
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. D. RICE, J. E. BUSH, and S. L. BROWER Assessment of Erlotinib in Chemoresponse Assay Anticancer Res, June 1, 2009; 29(6): 1993 - 1997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Eberhard, G. Giaccone, and B. E. Johnson Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting J. Clin. Oncol., February 20, 2008; 26(6): 983 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Toschi and F. Cappuzzo Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Oncologist, February 1, 2007; 12(2): 211 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. Siegel-Lakhai, J. H. Beijnen, and J. H.M. Schellens Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva(R)) and Gefitinib (Iressa(R)) Oncologist, September 1, 2005; 10(8): 579 - 589. [Abstract] [Full Text] [PDF]
|
|